Sanofi agreed to acquire Vigil Neuroscience for $8.00/share cash plus non-tradeable CVR of $2.00/share tied to first commercial sale of VG-3927, for total equity value up to ~$600M. Adds oral TREM2 agonist for Alzheimer's disease to Sanofi's neurology pipeline.